Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany

Author:

Wendler Julia1,Kroiss Matthias1,Gast Katja2,Kreissl Michael C3,Allelein Stephanie4,Lichtenauer Urs5,Blaser Rainer6,Spitzweg Christine2,Fassnacht Martin7,Schott Matthias5,Führer Dagmar8,Tiedje Vera8

Affiliation:

1. 1Department of Internal Medicine IDivision of Endocrinology and Diabetes, University of Würzburg, University Hospital Würzburg, Würzburg, Germany

2. 2Department of Internal Medicine IIUniversity Hospital Munich, Ludwig-Maximilians-Universität Munich, München, Germany

3. 3Department of Nuclear MedicineCentral Hospital Augsburg, Augsburg, Germany

4. 4Division for Specific EndocrinologyUniversity Hospital Düsseldorf, Düsseldorf, Germany

5. 5Department of Internal Medicine IVUniversity Hospital Munich, Ludwig-Maximilians-Universität München, München, Germany

6. 6Technical University MunichKlinikum rechts der Isar, Institute for Medical Statistics and Epidemiology, München, Germany

7. 7University of WürzburgComprehensive Cancer Center, Würzburg, Germany

8. 8Department of Endocrinology and MetabolismUniversity Hospital Essen, University Duisburg-Essen, Essen, Germany

Abstract

Context Anaplastic thyroid carcinoma (ATC) is an orphan disease and confers a dismal prognosis. Standard treatment is not established. Objective The aim of this study is to describe clinical characteristics, current treatment regimens and outcome of ATC and to identify clinical prognostic markers and treatment factors associated with improved prognosis. Design Retrospective cohort study at five German tertiary care centers. Patients and methods Totally 100 ATC patients diagnosed between 2000 and 2015 were included in the analysis. Disease-specific overall survival (OS) was compared with the Kaplan–Meier method and log-rank test; Cox proportional hazard model was used to identify risk factors. Results The 6-month, 1-year and 5-year disease-specific OS rates were 37, 28 and 5%, respectively. Stage-dependent OS at 6 months was 78, 54 and 18% for stage IVA, B and C, respectively. 29% patients survived >1 year. Multivariate analysis of OS identified age ≥70 years, incomplete local resection status and the presence of distant metastasis as significant risk factors associated with shorter survival. Radical surgery (hazard ratio [HR] 2.20, 95% confidence interval (CI) 1.19–4.09, P = 0.012), external beam radiation therapy (EBRT) ≥40 Gy (HR = 0.34, 0.15–0.76, P = 0.008) and any kind of chemotherapy (CTX) (HR = 11.64, 2.42–60.39, P = 0.003) were associated with longer survival in multivariate analyses adjusted for age and tumor stage. A multimodal treatment regimen was significantly associated with a survival benefit (HR = 1.04, 1.01–1.08, P < 0.0001) only in IVC patients. Conclusion Disease-specific OS is still poor in ATC. Treatment factors associated with improved OS provide a rationale to devise treatment pathways for routine care. Collaborative research structures should be aimed to advance treatment of ATC.

Publisher

Bioscientifica

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism

Cited by 87 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3